体重減少は,肥満の閉経後の女性のC反応性タンパク質のレベルを低下させる
André Tchernof1, Amy Nolan, Cynthia K Sites
1Department of Medicine, College of Medicine, University of Vermont, Burlington.
Circulation
|February 6, 2002
まとめ
体重減少は,肥満の閉経後の女性のC反応性タンパク質 (CRP) レベルを大幅に低下させる. 炎症のマーカーであるCRPの減少は,体重減少の心血管上の利点に寄与する可能性があります.
科学分野:
- 心血管疾患に関する研究
- 肥満と代謝の研究 肥満と代謝の研究
- 炎症バイオマーカー 炎症バイオマーカー
背景:
- C反応性タンパク質 (CRP) は,心血管疾患のリスクと関連しており,体重と肥満と好意的に関連しています.
- この研究では,体重減少が肥満の閉経後の女性におけるプラズマCRP濃度を低下させることができるかどうかを調査した.
研究 の 目的:
- 体重減少が肥満の閉経後の女性の血CRPレベルを低下させるかどうかを判断する.
- 脂肪とCRPレベルとの関係を調査する.
主な方法:
- 体脂肪とCRPの相関性を評価するために61人の肥満の閉経後の女性の横断分析.
- 減量プロトコルを受けた25人の女性を対象とした介入研究.
- 測定には,二重X線吸収計,CTスキャン,および高インスリン血症-ユーグリセミクランプが含まれていました.
主要な成果:
- 血のCRPレベルは,全身脂肪と腹内脂肪領域と正に相関しています.
- また,CRPとトリグリセリド濃度,およびグルコース排出量との間に有意な相関が認められた.
- 体重減少 (平均15.6%) は,血のCRPレベルを32.3% (P<0.0001) 減少させた.
結論:
- 肥満は,閉経後の肥満女性におけるプラズマCRPの有意な予測因子である.
- カロリー制限による体重減少は,プラズマのCRPレベルを効果的に低下させます.
- 体重減少は,CRPを低下させ,心臓保護効果を媒介する重要な介入かもしれません.
関連する概念動画
01:24Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
01:28Menopause
5.0K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.0K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
440
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
01:28Chronic Kidney Disease III: Interprofessional Care
679
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
679